Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

<p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Repres...

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Michael Kilian (16697663) (author)
Diğer Yazarlar:	Mirco Friedrich (3721555) (author), Khwab Sanghvi (16697666) (author), Edward Green (3822586) (author), Stefan Pusch (14934437) (author), Daisuke Kawauchi (15115187) (author), Martin Löwer (133159) (author), Jana K. Sonner (16697669) (author), Christopher Krämer (16697672) (author), Julia Zaman (16697675) (author), Stefanie Jung (554730) (author), Michael O. Breckwoldt (16697678) (author), Gerald Willimsky (16697681) (author), Stefan B. Eichmüller (16697684) (author), Andreas von Deimling (15037904) (author), Wolfgang Wick (15018168) (author), Felix Sahm (15097382) (author), Michael Platten (15018165) (author), Lukas Bunse (16697687) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Yazar:: Isha Mondal (16721699)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Yazar:: Mengjie Zhao (14845174)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Yazar:: Mengjie Zhao (14845174)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Yazar:: Mengjie Zhao (14845174)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Yazar:: Mengjie Zhao (14845174)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Yazar:: Mengjie Zhao (14845174)
Baskı/Yayın Bilgisi: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Yazar:: Defne Bayik (14961098)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
Yazar:: Bachchu Lal (17141949)
Baskı/Yayın Bilgisi: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Yazar:: Reza Mirzaei (15306062)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v64ttofar3nv52tobtgq5qk3oj